XOMA Corporation (XOMA) - Financial and Strategic SWOT Analysis
Review
Reference Code: GDPH81739FSA Publication Date: APR 2012
2910 Seventh Street Phone +1 510 2047200 Revenue 58.2 (million USD)
Berkeley, CA Fax +1 302 6555049 Net Profit -32.74 (million USD)
94710 Website www.xoma.com Employees 188
Pharmaceuticals &
United States Exchange XOMA [NASDAQ] Industry
Healthcare
Company Overview
Xoma Corporation (Xoma), formerly Xoma Ltd., is a biopharmaceutical company that discovers, develops therapeutics based on
monoclonal antibodies for the treatment of inflammatory diseases, autoimmune disorders, infectious diseases and various types
of cancer. It has licensed it monoclonal technologies to major biotechnology and pharmaceutical companies for the development
of biologics. Leveraging its expertise, technologies, and collaborative agreements it also developed a potential product pipeline
including it lead product, Gevokizumab (formerly called XOMA 052), a humanized antibody to interleukin-1ß (IL-1ß) for the
treatment of inflammation in several disorders.
Key Executives SWOT Analysis
Name Title XOMA Corporation, SWOT Analysis
Dr. Patrick J. Scannon, Chief Scientific Officer Strengths Weaknesses
M.D., Ph.D.
Strong In-house Research Customer Concentration
John Varian Chief Executive Officer
Capabilities
W. Denman Van Ness Chairman Decline in Financial
Operational Capabilities Performance
Peter Barton Hutt Director
William K. Bowes Jr. Director
Source: Annual Report, Company Website, Primary and Secondary
Opportunities Threats
Research, GlobalData
Changing Demographics Tightening of the FDA’s
Share Data Regulatory Oversight
Significant Agreements and
XOMA Corporation
Collaborations Uncertain R&D Outcomes
Share Price (USD) as on 13-Apr- 2.70
2012
Source: Annual Report, Company Website, Primary and Secondary Research,
EPS (USD) -1.04 GlobalData
Market Cap (million USD) 184
Enterprise Value (million USD) 157
Shares Outstanding (million) 68
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Financial Performance Recent Developments
Mar 14, 2012 XOMA Reports Revenue Of $9.8m In Q4 2011
Jan 05, 2012 XOMA Appoints John Varian As CEO
Jan 05, 2012 XOMA Streamlines Operations To Invest In
Value-Creating Activities
Dec 30, 2011 XOMA Moves Corporate Domicile To
Delaware
Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
XOMA Corporation (XOMA) - Financial and Strategic SWOT Reference Code: GDPH81739FSA
Analysis Review
Source : www.globalcompanyintelligence.com Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 4
List of Figures ................................................................................................................................................................................. 4
Section 1 - About the Company.......................................................................................................................................................... 5
XOMA Corporation - Key Facts .......................................................................................................................................................... 5
XOMA Corporation - Key Employees ................................................................................................................................................. 6
XOMA Corporation - Key Employee Biographies ............................................................................................................................... 7
XOMA Corporation - Major Products and Services ............................................................................................................................ 8
XOMA Corporation - Pharmaceutical Pipeline Products Data ............................................................................................................ 9
XOMA Corporation, Pipeline Products by Therapy Area ................................................................................................................ 9
XOMA Corporation, Pipeline Products by Development Phase .................................................................................................... 10
XOMA Corporation - History ............................................................................................................................................................. 12
XOMA Corporation - Company Statement ....................................................................................................................................... 16
XOMA Corporation - Locations And Subsidiaries ............................................................................................................................. 21
Head Office ................................................................................................................................................................................... 21
Other Locations & Subsidiaries ..................................................................................................................................................... 21
Section 2 – Company Analysis ......................................................................................................................................................... 22
XOMA Corporation - Business Description....................................................................................................................................... 22
XOMA Corporation - Corporate Strategy .......................................................................................................................................... 23
XOMA Corporation - SWOT Analysis ............................................................................................................................................... 24
SWOT Analysis - Overview........................................................................................................................................................... 24
XOMA Corporation - Strengths ..................................................................................................................................................... 24
Strength - Strong In-house Research Capabilities .................................................................................................................... 24
Strength - Operational Capabilities............................................................................................................................................ 24
Strength - Agreements with Servier........................................................................................................................................... 24
Strength - Orphan Drug Designation - Gevokizumab ............................................................................................................... 25
XOMA Corporation - Weaknesses ................................................................................................................................................ 25
Weakness - Customer Concentration........................................................................................................................................ 25
Weakness - Decline in Financial Performance .......................................................................................................................... 25
Weakness - Pending Legal Proceedings................................................................................................................................... 25
XOMA Corporation - Opportunities ............................................................................................................................................... 25
Opportunity - Changing Demographics ..................................................................................................................................... 25
Opportunity - Significant Agreements and Collaborations ......................................................................................................... 26
XOMA Corporation - Threats ........................................................................................................................................................ 26
Threat - Tightening of the FDA’s Regulatory Oversight ............................................................................................................. 26
Threat - Uncertain R&D Outcomes ........................................................................................................................................... 26
Threat - Competitive Landscape ............................................................................................................................................... 27
XOMA Corporation - Key Competitors ............................................................................................................................................. 28
Section 3 – Company Financial Ratios ............................................................................................................................................. 29
Financial Ratios - Capital Market Ratios........................................................................................................................................... 29
Financial Ratios - Annual Ratios ...................................................................................................................................................... 29
Performance Chart ........................................................................................................................................................................... 31
Financial Performance...................................................................................................................................................................... 31
Financial Ratios - Interim Ratios....................................................................................................................................................... 32
Financial Ratios - Ratio Charts ......................................................................................................................................................... 33
XOMA Corporation (XOMA) - Financial and Strategic SWOT Reference Code: GDPH81739FSA
Analysis Review
Source : www.globalcompanyintelligence.com Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 34
XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 .............................................................. 34
XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ............................................................. 35
XOMA Corporation, Recent Deals Summary ................................................................................................................................... 36
Section 5 – Company’s Recent Developments ................................................................................................................................ 37
XOMA Corporation, Recent Developments .................................................................................................................................. 37
Mar 14, 2012: XOMA Reports Revenue Of $9.8m In Q4 2011 ................................................................................................. 37
Jan 05, 2012: XOMA Appoints John Varian As CEO ................................................................................................................ 37
Jan 05, 2012: XOMA Streamlines Operations To Invest In Value-Creating Activities ............................................................... 38
Dec 30, 2011: XOMA Moves Corporate Domicile To Delaware ................................................................................................ 39
Nov 09, 2011: XOMA Reports Revenue Of $16.2m In Q3 2011 ............................................................................................... 39